14 results about "Lymphocyte infiltration" patented technology

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The invention discloses a construction method of a spontaneous lupus adipositis animal model, which comprises the following steps: constructing keratinocytes with genotypes of PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-Cre < + > / -and PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-CreERT < 2 + > / -and fat cells into a conditional PPAR [gamma]-active receptor gamma gene knockout mouse, so as to construct the animal model with the spontaneous lupus adipositis animal model. Then knocking out PPAR gamma genes in keratinocytes and adipocytes by using a gene knockout activator, so that the mice spontaneously have the phenotypes of lupus septicaemia, including local skin unhairing, lipoatrophy, persistent skin lesion, proteinuria and serum autoantibodies; histological examination finds that lobular adipositis, glomerular volume increase, mesangial cell hyperplasia, inflammatory cell infiltration, glomerular IgG deposition and the like are mainly caused by dermal immune cell infiltration and subcutaneous fat layer lymphocyte infiltration, clinical symptoms of patients with lupus adipositis are simulated, and an important tool is provided for related research of lupus adipositis.

The invention discloses an application of a TNFRSF12A inhibitor in preparation of a medicine for treating oral squamous cell carcinoma. Based on single cell transcriptome data, oral squamous cell canceration related tissues are divided into four tissue ecological subtypes, and a tumor sample is divided into two subtypes ET3 and ET4. The ET3 subtype is a lymphocyte infiltration type, and shows CD8 + T cell infiltration, immune activation pathway activity enhancement and high expression of CD3, CD8A and PDCD1; the ET4 subtype is a lymphocyte rejection type, is enriched with COL1A1 + fibroblasts, and is accompanied by high expression of TNFRSF12A, COL1A1 and CD276. According to the application disclosed by the invention, the expression of the TNFRSF12A in the ET4 subtype is obviously improved, in-vivo experiments prove that knockout or blocking of the TNFRSF12A can promote lymphatic T cell infiltration and inhibit tumor growth, and a stronger inhibition effect is shown when the knockout or blocking of the TNFRSF12A is combined with an immune checkpoint inhibitor. The invention provides a system for typing oral squamous cell carcinoma.

The application provides a bladder cancer immunophenotyping recognition method and system, comprising: preprocessing pathological image data to obtain preprocessed pathological image data; constructing a tumor and stroma region segmentation model based on a semantic segmentation network TransUNet, training the tumor and stroma region segmentation model using the preprocessed pathological image data and label data, and obtaining a trained tumor and stroma region segmentation model; constructing a TIL recognition neural network model classification model based on Resnet50 using a tumor and stroma segmentation result output by the trained tumor and stroma region segmentation model; and obtaining a bladder cancer immunophenotyping result based on a lymphocyte infiltration score output by the TIL recognition neural network model classification model. The application automatically recognizes a tumor region and immune cell distribution using digital pathological images, constructs a standardized immunoscore and typing method, and improves the individual decision-making ability of clinical immunotherapy.

The invention discloses application of sitagliptin in preparation of a medicine for treating Graves eye diseases, and belongs to the field of biological medicine. The invention discloses the application of sitagliptin in preparation of the medicine for treating Graves eye diseases for the first time, and sitagliptin can improve expression of CD4 + CTL cytotoxic functional molecules and improve eye symptoms, extraocular muscle thickening and fibrosis, orbit fat neogenesis and orbit T lymphocyte infiltration of mice; the mouse spleen CD4 + CTL cell proportion is improved; in addition, the thyroid hormone level, thyroid hyperplasia and hypertrophy and lymphocyte infiltration of mice can be improved. Sitagliptin is a clinically common hypoglycemic drug, and is perfect in safety database, small in side effect and easy to popularize clinically. Therefore, the experimental result of the invention fully supports the new application of sitagliptin in treating Graves eye diseases, and is a new direction worthy of exploration for treating Graves eye diseases due to strong clinical operability.

The application discloses application of chrysin in preparation of a medicine for treating primary Sjogren's syndrome and belongs to the technical field of biological medicine. The application proves that chrysin can be specifically combined with TNFR2 protein and is a new type of TNFR2 inhibitor through molecular docking, molecular dynamics simulation, CETSA experiment and SPR experiment. Animal experiments show that chrysin can significantly increase the secretion amount of saliva and tear of a mouse model of primary Sjogren's syndrome, reduce the serum SSA and SSB antibody levels, reduce lymphocyte infiltration and acinus atrophy of submandibular glands and lacrimal glands, inhibit the expression of a cytokine INF-gamma, and the drug efficacy is equivalent to that of a positive medicine hydroxychloroquine; chrysin and gaoshunyujin have a synergistic effect, and the improvement effect on primary Sjogren's syndrome is better than that of hydroxychloroquine. The application provides a new medical use of chrysin, and provides a safe and effective prevention and treatment medicine for primary Sjogren's syndrome.

The invention belongs to the field of biotechnology and medicine, discloses application of an SIRT1 protein activator in preparation of an anti-inflammatory immune drug, and creatively provides application of the SIRT1 protein activator in preparation of the anti-inflammatory immune drug. The SIRT1 activator is especially applied to drugs for treating autoimmune diseases with external secretory gland lymphocyte infiltration and I-type interferon (IFN) characteristic excessive activation as the core, and the SIRT1 activator inhibits I-type interferon excessive activation through targeted regulation, so that the SIRT1 activator has a good clinical application prospect in relieving and treating sicca syndrome. And the method has a wide application scene and a practical practical value.

The application provides a traditional Chinese medicine composition for treating or improving Sjogren's syndrome, and belongs to the technical field of traditional Chinese medicine pharmacy.The traditional Chinese medicine composition takes asparagus, lily and mulberry as monarch drugs, takes honeysuckle, semen astragali, rush and radix codonopsis as minister drugs, takes turmeric and atractylodes as auxiliary drugs, and takes licorice as a guide drug, and the drugs are combined to have the effects of nourishing yin and moistening dryness, clearing heat and dredging collaterals, tonifying qi and invigorating the spleen, and promoting blood circulation and improving eyesight.The traditional Chinese medicine composition can significantly reduce the water consumption of NOD mice, increase the saliva amount of NOD mice, significantly down-regulate the levels of inflammatory factors TNF-alpha, IL-17 and IL-1beta in the serum of NOD mice, improve the gland structure and lymphocyte infiltration in the submandibular gland tissue of NOD mice, and reduce the submandibular gland injury.In addition, the traditional Chinese medicine composition can significantly reduce the ESSDAI and ESSPRI scores of Sjogren's syndrome patients, improve the clinical symptoms such as dry mouth, dry eyes and salivary gland swelling of the patients, has a high total effective rate in clinical treatment, and can be further developed and researched as a drug for treating Sjogren's syndrome.

The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor. The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and / or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1 / PD-L1 monotherapy.

The invention provides a traditional Chinese medicine composition for treating or improving sicca syndrome, and belongs to the technical field of traditional Chinese medicine pharmacy. According to the traditional Chinese medicine composition, radix asparagi, lilies and mulberries are used as monarch drugs, honeysuckle stems, pipewort, juncus roemerianus and codonopsis pilosula are used as ministerial drugs, turmeric and rhizoma atractylodis are used as adjuvant drugs, liquorice is used as conductant drugs, and all the drugs are combined to achieve the effects of nourishing yin, moistening dryness, clearing heat, dredging collaterals, replenishing qi, invigorating the spleen, activating blood and improving eyesight. The traditional Chinese medicine composition can significantly reduce the water intake of NOD mice, increase the saliva volume of the NOD mice, significantly reduce the levels of inflammatory factors TNF-alpha, IL-17 and IL-1beta in serum of the NOD mice, improve the gland structure and lymphocyte infiltration condition in submaxillary gland tissue of the NOD mice, and relieve submaxillary gland injury. Besides, the traditional Chinese medicine composition can remarkably reduce ESSDAI and ESSPRI scores of sicca syndrome patients and improve the clinical symptoms such as mouth dryness, eye dryness and salivary gland swelling of the patients, has high clinical treatment total effective rate and can be used as a medicine for treating the sicca syndrome to be further developed and researched.

Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.

This invention discloses the application of geraniol in the preparation of a drug for treating Sjögren's syndrome. In vivo experiments using a NOD mouse model of Sjögren's syndrome demonstrated that geraniol treatment significantly improved salivary secretion disorders and reduced abnormally high water intake in the mice; significantly reduced lymphocyte infiltration in salivary gland tissue, improved glandular pathological damage, downregulated the levels of characteristic autoantibodies (Anti-SSA / Ro and Anti-SSB / La) in serum, upregulated the expression levels of AQP5 and AR, and reduced organ indices in salivary glands, spleen, and thymus tissue, comprehensively improving dry mouth symptoms in mice. In vitro experiments also showed that geraniol treatment upregulated the expression levels of AQP5 and AR. Therefore, this invention provides the application of geraniol in the preparation of a drug for treating Sjögren's syndrome, which has the advantages of significant efficacy and addressing both the symptoms and root cause, and possesses good clinical application prospects.

The application relates to the field of biological medicine, and discloses a medicine for relieving autoimmune prostatitis and application thereof, which comprises an active ingredient and a pharmaceutically acceptable sterile phosphate buffer carrier; the active ingredient is live Lactobacillus johnsonii with a number of BNCC135265 or extracellular vesicles of Lactobacillus johnsonii; the final concentration of live bacteria in the medicine is 1x10 8 to 1x10 10 CFU / mL, which is used for preparing a preparation for intragastric administration; the extracellular vesicles contain 1x10 8 to 5x10 9 particles per unit dosage form, which is used for preparing a preparation for tail vein injection administration. By using the live bacteria with the specific number or the extracellular vesicles thereof, intestinal mucosa colonization can be achieved to block endotoxin into blood, or the extracellular vesicles can be enriched in prostate lesions to inhibit a nuclear factor-kappa B inflammatory signaling pathway, reduce synthesis of proinflammatory cytokines and lymphocyte infiltration, and finally realize relief of autoimmune prostatitis.

The application discloses application of dihydroeugenol in preparation of a medicine for treating Sjogren's syndrome. Through in-vivo experiments of a Sjogren's syndrome model of NOD mice, it is proved that after dihydroeugenol treatment, the saliva secretion disorder of the Sjogren's syndrome model mice can be significantly improved, the abnormally increased water consumption can be reduced, the lymphocyte infiltration of the salivary gland tissue can be significantly reduced, the pathological damage of the gland can be improved, the level of the characteristic autoantibody (Anti-SSA / Ro and Anti-SSB / La) in serum can be lowered, the expression level of AQP5 and AR can be raised, the organ index of the salivary gland, spleen and thymus tissue can be reduced, and the dry mouth symptom of the mice is comprehensively improved. In-vitro experiments also show that after dihydroeugenol treatment, the expression level of AQP5 and AR can be raised. Therefore, the application of dihydroeugenol in preparation of the medicine for treating Sjogren's syndrome has the advantages of significant curative effect, treating both the symptoms and the root cause, and good clinical application prospect.